Developing new drugs for the treatment of sarcoidosis isn’t easy. First, the cause of sarcoidosis is unknown. Second, prednisone, a remarkably effective medication for the treatment of sarcoidosis, limited only by its adverse side effect profile, is tough to beat. Third, sarcoidosis is a rare disease, which affects fewer than 200,000 people in the US per year. These challenges notwithstanding, researchers at Mount Sinai will be testing a new drug for the treatment of sarcoidosis. In late 2015, the Division of Pulmonary, Critical Care and Sleep Medicine will be enrolling sarcoidosis patients, who meet prespecified entry criteria, into a clinical trial to evaluate the efficacy and safety of KiactaTM for the treatment of sarcoidosis.
Sarcoidosis is a multisystem, inflammatory disease, which can involve all organ systems to a varying degree and extent. Upon diagnosis or afterward, patients are commonly overwhelmed by their disease and frequently ask questions that include: How did I get this disease; Will it spread to all my organs; Will it kill me; which of my other ailments are related to sarcoidosis and do I need treatment for them; Can I expect to live a normal life; Should I be on a special diet; Will my kids inherit sarcoidosis?